- Home
- OI vs ARDX Comparison
OI vs ARDX Comparison
Compare OI & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OI | ARDX |
|---|---|---|
| Founded | 1903 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.8M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OI | ARDX |
|---|---|---|
| Price | $6.51 | $4.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $15.29 | $15.14 |
| AVG Volume (30 Days) | 3.2M | ★ 4.4M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,426,000,000.00 | $2,607,000.00 |
| Revenue This Year | $2.77 | $37.75 |
| Revenue Next Year | $1.88 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.35 | $3.86 |
| 52 Week High | $16.91 | $8.40 |
Technical Indicators
Market Signals| Indicator | OI | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.02 | 29.69 |
| Support Level | N/A | N/A |
| Resistance Level | $9.63 | $6.16 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 11.79 | 14.13 |
Price Performance
Historical ComparisonAbout OI O-I Glass Inc.
O-I Glass is the manufacturer of glass containers. The Company has two reportable segments and two operating segments based on its geographic locations: Americas and Europe. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.